Table 1.

D’Amico risk stratification of prostate cancer²

	PSA ng/mL	Gleason sum	Clinical stage
Low risk	≤10	≤6	≤T2a
Intermediate risk	10–20	7	T2b
High risk	≥20	8–10	≥T2c